VBP-245

Veloce BioPharma LLC · Phase 2 active Small molecule

At a glance

Generic name	VBP-245
Sponsor	Veloce BioPharma LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Topical 2% Povidone-Iodine Gel in Verruca Vulgaris (PHASE2)
A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VBP-245 CI brief — competitive landscape report
VBP-245 updates RSS · CI watch RSS
Veloce BioPharma LLC portfolio CI